Your browser is no longer supported. Please, upgrade your browser.
VCYT [NASD]
Veracyte, Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own0.90% Shs Outstand57.90M Perf Week-2.31%
Market Cap2.86B Forward P/E- EPS next Y-0.30 Insider Trans-46.88% Shs Float57.52M Perf Month-6.33%
Income-34.30M PEG- EPS next Q-0.11 Inst Own- Short Float7.25% Perf Quarter18.67%
Sales112.70M P/S25.40 EPS this Y56.00% Inst Trans0.22% Short Ratio6.65 Perf Half Y64.16%
Book/sh7.71 P/B6.59 EPS next Y52.40% ROA-11.00% Target Price46.20 Perf Year68.35%
Cash/sh6.12 P/C8.29 EPS next 5Y- ROE-12.30% 52W Range13.90 - 63.55 Perf YTD3.78%
Dividend- P/FCF- EPS past 5Y27.40% ROI-6.30% 52W High-20.08% Beta0.72
Dividend %- Quick Ratio26.30 Sales past 5Y25.80% Gross Margin64.20% 52W Low265.40% ATR3.90
Employees354 Current Ratio26.60 Sales Q/Q0.30% Oper. Margin-31.60% RSI (14)49.55 Volatility6.80% 8.06%
OptionableYes Debt/Eq0.00 EPS Q/Q-400.50% Profit Margin-30.50% Rel Volume0.96 Prev Close52.58
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout- Avg Volume626.57K Price50.79
Recom2.00 SMA20-0.20% SMA500.08% SMA20044.72% Volume601,851 Change-3.40%
Nov-10-20Initiated KeyBanc Capital Markets Sector Weight $48
Sep-09-20Initiated Morgan Stanley Underweight $35
Jul-31-19Initiated Lake Street Buy $35
Jul-02-19Initiated Needham Buy $33
Nov-29-18Downgrade Janney Buy → Neutral
Oct-31-18Upgrade Janney Neutral → Buy
Nov-07-17Downgrade Piper Jaffray Overweight → Neutral
Nov-07-17Downgrade Janney Buy → Neutral
Aug-31-17Resumed BTIG Research Buy $13
Nov-14-16Resumed Leerink Partners Outperform $12
Dec-18-15Initiated Cantor Fitzgerald Buy $13
Jun-11-15Reiterated Leerink Partners Outperform $11 → $13
Nov-26-13Initiated William Blair Outperform
Jan-06-21 02:00PM  
Dec-23-20 08:00AM  
Dec-22-20 08:52AM  
08:15AM  
Dec-21-20 08:15AM  
Dec-16-20 12:00PM  
Dec-15-20 05:59PM  
08:15AM  
Dec-11-20 10:00PM  
Dec-03-20 02:30PM  
Nov-23-20 04:05PM  
Nov-17-20 09:45AM  
Nov-16-20 03:19PM  
Nov-05-20 03:05AM  
Nov-04-20 12:42PM  
Nov-02-20 06:55PM  
04:05PM  
02:30PM  
Oct-30-20 08:15AM  
Oct-26-20 12:31PM  
Oct-22-20 04:05PM  
Oct-19-20 08:15AM  
Oct-14-20 04:05PM  
Oct-07-20 08:15AM  
Sep-24-20 08:15AM  
Sep-15-20 04:30PM  
Sep-14-20 01:45PM  
Sep-11-20 08:15AM  
Sep-09-20 09:44AM  
Sep-04-20 08:15AM  
Aug-24-20 08:15AM  
Aug-07-20 04:15PM  
Aug-05-20 04:15PM  
03:26PM  
08:15AM  
Aug-04-20 07:27PM  
Aug-03-20 04:10PM  
Aug-02-20 10:53AM  
Jul-30-20 07:10PM  
04:05PM  
08:15AM  
Jul-29-20 08:15AM  
Jul-27-20 08:15AM  
Jul-23-20 12:33PM  
Jul-16-20 07:21PM  
08:15AM  
Jul-05-20 05:06PM  
Jun-29-20 02:06PM  
Jun-11-20 08:23AM  
07:30AM  
Jun-09-20 08:15AM  
Jun-04-20 05:00PM  
May-27-20 08:15AM  
May-22-20 06:22PM  
07:29AM  
May-21-20 08:15AM  
May-18-20 03:42PM  
08:25AM  
May-14-20 08:15AM  
May-07-20 04:05PM  
09:31AM  
May-06-20 07:05PM  
04:05PM  
03:00PM  
May-01-20 08:15AM  
Apr-29-20 12:34PM  
Apr-23-20 01:07PM  
Apr-17-20 07:35AM  
Apr-16-20 04:30PM  
Apr-13-20 10:54AM  
Apr-08-20 07:00PM  
Apr-07-20 08:15AM  
Apr-02-20 08:38AM  
Apr-01-20 08:15AM  
Mar-10-20 03:18AM  
Mar-02-20 11:00AM  
Feb-26-20 10:28AM  
Feb-25-20 06:05PM  
04:05PM  
Feb-13-20 08:15AM  
Feb-06-20 01:30PM  
Jan-20-20 02:44PM  
Jan-08-20 08:15AM  
Dec-13-19 09:06AM  
Dec-04-19 11:56AM  
07:06AM  
Dec-03-19 06:05PM  
05:09PM  
05:00PM  
Nov-02-19 09:30AM  
Oct-31-19 04:30AM  
Oct-30-19 08:15AM  
Oct-27-19 02:00PM  
Oct-24-19 06:42AM  
Oct-22-19 04:15PM  
07:00AM  
Oct-21-19 04:15PM  
09:57AM  
Oct-09-19 03:14PM  
Oct-08-19 04:30PM  
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson Bonnie HChairman and CEOJan 13Option Exercise5.6118,541104,015222,297Jan 15 05:03 PM
Anderson Bonnie HChairman and CEOJan 13Sale51.0518,541946,462203,756Jan 15 05:03 PM
Anderson Bonnie HChairman and CEOJan 12Option Exercise5.6120,354114,186224,110Jan 13 05:11 PM
Anderson Bonnie HChairman and CEOJan 12Sale50.2020,3541,021,772203,756Jan 13 05:11 PM
Anderson Bonnie HChairman and CEOJan 11Option Exercise8.5971,105610,741274,861Jan 13 05:11 PM
Anderson Bonnie HChairman and CEOJan 11Sale50.6271,1053,599,303203,756Jan 13 05:11 PM
GORDON KEVIN KDirectorJan 04Option Exercise7.3910,00073,90010,000Jan 05 05:00 PM
GORDON KEVIN KDirectorJan 04Sale48.9810,000489,7980Jan 05 05:00 PM
Anderson Bonnie HChairman and CEODec 29Option Exercise3.7331,313116,919203,756Dec 30 05:54 PM
Kennedy Giulia CChief Scientific & Med OfficerDec 04Option Exercise11.1513,468150,20992,327Dec 04 07:42 PM
Kennedy Giulia CChief Scientific & Med OfficerDec 04Sale56.8814,015797,15678,312Dec 04 07:42 PM
GORDON KEVIN KDirectorNov 12Option Exercise7.3910,00073,90010,000Nov 13 05:07 PM
GORDON KEVIN KDirectorNov 12Sale47.1110,000471,1380Nov 13 05:07 PM
Ho MarkPrincipal Accounting OfficerNov 11Sale45.0013,875624,37519,086Nov 13 05:04 PM
Anderson Bonnie HChairman and CEONov 10Option Exercise8.8620,000177,200240,231Nov 12 05:12 PM
Hanna John Walter JRChief Commercial OfficerNov 06Option Exercise20.2121,250429,46395,559Nov 09 04:48 PM
Hanna John Walter JRChief Commercial OfficerNov 06Sale43.4421,250923,10674,309Nov 09 04:48 PM
Hanna John Walter JRChief Commercial OfficerNov 05Option Exercise7.486,40647,90280,715Nov 06 04:10 PM
Hanna John Walter JRChief Commercial OfficerNov 05Sale40.696,406260,65174,309Nov 06 04:10 PM
Ho MarkPrincipal Accounting OfficerOct 20Option Exercise6.457,50048,37532,961Oct 21 06:22 PM
Cohen Fred EDirectorOct 19Option Exercise7.6010,00076,00010,000Oct 20 05:40 PM
Anderson Bonnie HChairman and CEOOct 08Option Exercise8.8650,000443,000270,231Oct 09 05:07 PM
Anderson Bonnie HChairman and CEOOct 08Sale38.0050,0001,900,000220,231Oct 09 05:07 PM
Kennedy Giulia CChief Scientific & Med OfficerOct 06Option Exercise20.212,50050,52581,899Oct 07 05:06 PM
Kennedy Giulia CChief Scientific & Med OfficerOct 06Sale35.212,50088,02579,399Oct 07 05:06 PM
Anderson Bonnie HChairman and CEOSep 10Option Exercise8.8620,000177,200240,231Sep 14 05:11 PM
Anderson Bonnie HChairman and CEOSep 10Sale30.8920,000617,861220,231Sep 14 05:11 PM
Kennedy Giulia CChief Scientific & Med OfficerSep 04Option Exercise7.666,47949,61886,426Sep 08 05:54 PM
Kennedy Giulia CChief Scientific & Med OfficerSep 04Sale31.107,027218,56479,399Sep 08 05:54 PM
Hanna John Walter JRChief Commercial OfficerAug 31Option Exercise8.4356,443475,978131,077Sep 01 05:08 PM
Hanna John Walter JRChief Commercial OfficerAug 31Sale33.3756,4431,883,55074,634Sep 01 05:08 PM
Hanna John Walter JRChief Commercial OfficerAug 21Option Exercise8.861,40012,40476,034Aug 25 05:10 PM
Hanna John Walter JRChief Commercial OfficerAug 21Sale36.001,40050,40574,634Aug 25 05:10 PM
Anderson Bonnie HChairman and CEOAug 10Option Exercise8.8620,000177,200242,207Aug 12 06:37 PM
JONES EVAN/ FADirectorAug 03Sale35.1620,000703,11769,653Aug 04 07:59 PM
Kennedy Giulia CChief Scientific & Med OfficerJul 31Option Exercise20.2120,000404,200100,487Aug 04 08:05 PM
Hanna John Walter JRChief Commercial OfficerJul 31Option Exercise8.8614,095124,88288,729Aug 04 08:11 PM
Hanna John Walter JRChief Commercial OfficerJul 31Sale36.1214,095509,14574,634Aug 04 08:11 PM
Kennedy Giulia CChief Scientific & Med OfficerJul 31Sale35.3320,000706,69480,487Aug 04 08:05 PM
JONES EVAN/ FADirectorJul 31Sale35.6720,000713,30689,653Aug 04 07:59 PM
Anderson Bonnie HChairman and CEOJul 30Option Exercise8.8611,365100,694283,572Jul 31 04:32 PM
Anderson Bonnie HChairman and CEOJul 30Sale32.2411,365366,399272,207Jul 31 04:32 PM
Anderson Bonnie HChairman and CEOJul 23Option Exercise8.863,28029,061275,487Jul 27 05:04 PM
Anderson Bonnie HChairman and CEOJul 23Sale32.043,280105,106272,207Jul 27 05:04 PM
Anderson Bonnie HChairman and CEOJul 22Option Exercise8.86100886272,307Jul 22 06:09 PM
Anderson Bonnie HChairman and CEOJul 22Sale32.001003,200272,207Jul 22 06:09 PM
Hanna John Walter JRChief Commercial OfficerJul 21Option Exercise2.406531,56775,177Jul 22 06:16 PM
Anderson Bonnie HChairman and CEOJul 21Option Exercise8.863,44730,540275,654Jul 22 06:09 PM
Hanna John Walter JRChief Commercial OfficerJul 21Sale32.3665321,13174,524Jul 22 06:16 PM
Anderson Bonnie HChairman and CEOJul 21Sale32.093,447110,614272,207Jul 22 06:09 PM
Anderson Bonnie HChairman and CEOJul 20Option Exercise8.4220,349171,287292,556Jul 22 06:09 PM
Hanna John Walter JRChief Commercial OfficerJul 20Option Exercise2.4011,29427,10685,818Jul 22 06:16 PM
Hanna John Walter JRChief Commercial OfficerJul 20Sale32.0511,294361,99374,524Jul 22 06:16 PM
Anderson Bonnie HChairman and CEOJul 20Sale32.0420,349651,911272,207Jul 22 06:09 PM
JONES EVAN/ FADirectorJul 15Sale30.1210,000301,192109,653Jul 16 05:15 PM
JONES EVAN/ FADirectorJul 14Sale28.3420,000566,847119,653Jul 16 05:15 PM
EPSTEIN ROBERT SDirectorJul 13Option Exercise5.2810,00052,80010,000Jul 14 08:26 PM
Kennedy Giulia CChief Scientific & Med OfficerJul 13Option Exercise13.0516,738218,37397,225Jul 14 08:29 PM
EPSTEIN ROBERT SDirectorJul 13Sale29.7310,000297,2520Jul 14 08:26 PM
Kennedy Giulia CChief Scientific & Med OfficerJul 13Sale29.6616,738496,47880,487Jul 14 08:29 PM
Kennedy KeithCOO / CFOJul 06Option Exercise7.6747,658365,351200,309Jul 07 05:47 PM
Kennedy KeithCOO / CFOJul 06Sale28.2180,6772,276,172119,632Jul 07 05:47 PM
Kennedy KeithCOO / CFOJul 02Option Exercise5.982,80016,744158,398Jul 07 05:47 PM
Kennedy KeithCOO / CFOJul 02Sale28.025,747161,040152,651Jul 07 05:47 PM
Anderson Bonnie HChairman and CEOJun 10Option Exercise4.0020,00080,000292,207Jun 11 07:06 PM
Anderson Bonnie HChairman and CEOJun 10Sale26.5620,000531,260272,207Jun 11 07:06 PM
Kennedy Giulia CChief Scientific & Med OfficerJun 03Option Exercise7.5410,23977,25191,273Jun 04 04:16 PM
Kennedy Giulia CChief Scientific & Med OfficerJun 03Sale26.2210,786282,80980,487Jun 04 04:16 PM
Cohen Fred EDirectorMay 18Sale26.8640,0001,074,5550May 19 04:04 PM
Anderson Bonnie HChairman and CEOMay 11Option Exercise4.0020,00080,000294,183May 13 04:47 PM
Anderson Bonnie HChairman and CEOMay 11Sale26.6720,000533,334274,183May 13 04:47 PM
Anderson Bonnie HChairman and CEOMar 20Option Exercise2.6816,00042,880272,313Mar 23 05:01 PM
Anderson Bonnie HChairman and CEOMar 10Option Exercise4.0020,00080,000276,313Mar 11 05:05 PM
Anderson Bonnie HChairman and CEOMar 10Sale25.1820,000503,520256,313Mar 11 05:05 PM
Kennedy Giulia CChief Scientific & Med OfficerMar 03Option Exercise7.1315,033107,111114,155Mar 04 05:49 PM
Kennedy Giulia CChief Scientific & Med OfficerMar 03Sale25.3932,881834,79881,274Mar 04 05:49 PM